myositis, vasculitis, and gout. We herein present a patient mimicking SLE who was diagnosed with HIV.

**Methods** A 40-year-old man presented with a 3-month history of oral lesions and a 2-month history of blurry vision, vertigo, speech difficulty, and ataxic gait. His past medical history was unremarkable. His vital findings were within normal ranges. There were two oral lesions that were greater than 10 mm in diameter localized on the hard palate and tongue. Cerebellar tests including gait, finger-to-nose, and heel-to-shin were abnormal. He could not walk in tandem gait. However, muscle strength and sensory exam were normal.

On laboratory outcomes, fasting blood glucose, blood urea nitrogen, creatinine, and thyroid-function tests were normal. The rest of laboratory data were as follows: ALT 129 U/L, AST 102 U/L, GGT 72 U/L, hemoglobin 12.3 mg/L, WBC 3.6×10³/mcL, neutrophil count 1.8×10³/mcL, lymphocyte count 1.2×10³/mcL, CRP 1.5 mg/dl (normal, ≤5 mg/dl), ESR 42 mm/h.

Cranial MRI was reported as multiple hyperintense spots located on supratentorial white matter, corpus callosum, and brainstem on standard T2-weighted MRI sequence. On neurological consultation, these lesions were interpreted as encephalitis. Additionally, he was consulted to Ophthalmologist due to blurry vision. No pathological finding was found. He was also for autoimmune disorders causing cerebral involvement. Thus, ANA, ENA, anti ds DNA, ANCA were investigated. All autoantibodies, hepatitis screening, CMV, EBV, parvovirus B 19 were found negative. On the other hand, HIV positivity was detected by ELISA. Consequently, the patient was transferred to department of Infectious diseases.

**Conclusion** HIV causes autoimmune and systemic disorders via triggering immune dysregulation. The frequency of these autoimmune diseases has ranged from 1% to 60% according to literature. Both HIV and the treatment of HIV can cause rheumatologic findings.

**Results** The mean age was 22.8±5.3 years with 90% females. Patients had a mean of 12.7±2.3 years of formal education. A mean MMSE of 27.7 (1.9) was found, and 23.3% of the population showed mild cognitive impairment. MMSE scores were negatively correlated with C-Reactive Protein (CRP) (r=-0.38, p=0.044) and platelet count (r=-0.37, p=0.044). Additionally, patients presenting positive anti-SSA (n=10), anti-RNP (n=4) and anti-SM (n=4) autoantibodies, scored significantly lower MMSE scores compared to patients without these autoantibodies (p=0.029; p=0.017 and p=0.017, respectively).

**Conclusions** Our population showed a low mean MMSE score, regardless of their educational level and age. The consistent relationship between the presence of cognitive impairment, higher inflammatory activity and autoantibodies frequently associated with neuropsychiatric involvement in JSLE seems to point to the need to screen JSLE populations for mild cognitive impairment with larger studies being required.

**Background** Concomitant presence of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient is known as Rhusus. Poliautoimmunity is not an uncommon phenomenon reported, but only a small series of patients have been described so far with Rhusus. This study aimed to explore the utility of 2019 EULAR/ACR criteria in patients with Rhusus.

**Methods** Cross-sectional study conducted in 11 Rheumatology Departments at Catalonia (Spain). We included prevalent cases classified as Rhusus (RA ACR/EULAR 2010 and SLE-ACR 1997). Data of patients with SLE were selected as control in a ratio 2:1, matched by sex.

**Results** 120 patients were included, 40 Rhusus and 80 SLE alone as controls. 95% were female, with a mean age of 51 yrs and mean of 13 yrs. The 2019 SLE EULAR/ACR criteria were met in 92.5% of the Rhusus and in the 96.3% of the SLE cohort (p>0.05). Numerically, criteria score was higher in those patients with ‘pure’ SLE than Rhusus (21.3±7.0 vs 18.8±6.5, p=NS). Excluding articular domain, there were no significant differences among those who meet new criteria (65% Rhusus vs. 77% SLE (p>0.05)). Proteinuria was the only domain significantly more common in patients with SLE alone. No other differences were found in other clinical or serological characteristics.

**Conclusion** More than 90% of patients classified as Rhusus criteria fulfilled new SLE criteria. This study shows that the new 2019 SLE EULAR/ACR criteria are not useful to differentiate SLE and Rhusus patients. Further investigations are needed to measure their utility in clinical practice for detecting overlap presentation of RA and SLE.